AL 335/odalasvir/simeprevir - Janssen/Medivir

Drug Profile

AL 335/odalasvir/simeprevir - Janssen/Medivir

Alternative Names: AL-335/odalasvir/simeprevir - Janssen/Medivir; JNJ-4178; odalasvir/simeprevir/AL-335 - Janssen/Medivir; simeprevir/AL-335/odalasvir - Janssen/Medivir

Latest Information Update: 19 Apr 2017

Price : $50

At a glance

  • Originator Janssen; Medivir AB
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 04 Apr 2017 Janssen Research & Development initiates enrolment in a long-term follow-up trial for Hepatitis C (In adults, In the elderly) in New Zealand (NCT03099135)
  • 20 Feb 2017 Phase-I clinical trials in Hepatitis C (In volunteers) in USA (PO) (NCT03059303)
  • 09 Feb 2017 Phase-II clinical trials in Hepatitis C (Treatment-experienced) in Belgium, Poland, Singapore and Spain (PO) before February 2017 (NCT02765490)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top